• Aucun résultat trouvé

Clinical performance of the Panbio assay for the detection of SARS‐CoV‐2 IgM and IgG in COVID‐19 patients

N/A
N/A
Protected

Academic year: 2021

Partager "Clinical performance of the Panbio assay for the detection of SARS‐CoV‐2 IgM and IgG in COVID‐19 patients"

Copied!
16
0
0

Texte intégral

Figure

Figure 1:  Kinetics of the sensitivity of the Panbio assay since the onset of  symptoms
Table 1: Evaluation of the impact of the rater and the time of reading on the IgG  (A) and IgM (B) test results

Références

Documents relatifs

Among the 79 samples evaluated 14 or more days after the onset of symptoms, and using the manufacturer’s cut-off, the Elecsys anti- SARS-CoV-2 assay identified 72 true positive and

Clinical performance of four immunoassays for antibodies to SARS-CoV-2, including a prospective analysis for the diagnosis of COVID-19 in a real-life routine care setting... 2

Antigen-detecting rapid diagnostic tests (Ag-RDTs) for the detection of SARS-CoV-2 offer new opportunities for testing in the context of the COVID-19 pandemic.. Nasopharyngeal

In this review, we cover bioinformatics workflows and tools for the routine detection of SARS-CoV-2 infection, the reliable analysis of sequencing data, the tracking of the

To expand the understanding of clinical characteristics and prognostic factors among patients hospitalized with suspected or confirmed COVID-19, and to inform optimal